Ignyta Announces Underwriters’ Full Exercise Of Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced the underwriters’ full exercise of the option granted to the underwriters to purchase an additional 786,750 shares of the company’s common stock, at a price to the public of $9.15 per share. The option to purchase the additional shares was granted in connection with the company's previously announced underwritten public offering of 5,245,000 shares of its common stock. The exercise of the option brings the expected total gross proceeds from the offering to approximately $55.2 million.

Help employers find you! Check out all the jobs and post your resume.